欢迎访问《中国临床药理学与治疗学》杂志官方网站,今天是

中国临床药理学与治疗学 ›› 2017, Vol. 22 ›› Issue (8): 927-932.

• 药物治疗学 • 上一篇    下一篇

Syndecan-1在结直肠癌中的表达与EGFR表达、K-Ras突变及化疗疗效相关性分析

原少斐,朱林佳,郑维锷,梁美珍   

  1. 温州医科大学附属第三医院肿瘤中心,温州 325200,浙江
  • 收稿日期:2016-12-30 修回日期:2017-02-14 出版日期:2017-08-26 发布日期:2017-08-18
  • 通讯作者: 梁美珍,女,博士,副教授,研究方向:肿瘤精准治疗。 Tel:0577-65866340 E-mail: kitty.linjia@163.com
  • 作者简介:原少斐,男,硕士,讲师,研究方向:肿瘤化学治疗。 Tel:0577-65866342 E-mail: ysf1004@163.com
  • 基金资助:

    浙江省科技计划项目(2016L10320)

Relationship of Syndecan-1 and EGFR expression, K-Ras gene mutations and response to FOLFOX in advanced colorectal carcinoma

YUAN Shaofei, ZHU Linjia, ZHENG Weie, LIANG Meizhen   

  1. Oncology Department, the Third Affiliated Hospital, Wenzhou Medical University, Wenzhou 325200, Zhejiang, China
  • Received:2016-12-30 Revised:2017-02-14 Online:2017-08-26 Published:2017-08-18

摘要:

目的: 探讨结直肠癌中Syndecan-1的表达与表皮生长因子受体(epidermal growth factorreceptor,EGFR)表达、K-Ras基因突变及化疗疗效的关系。方法: 利用免疫组织化学法检测160例晚期结直肠癌患者中Syndecan-1的表达情况,分析其与患者临床病理特征、分子标志物及FOLFOX方案化疗疗效的相关性。结果: 所有患者中有41例(25.6%)Syndecan-1表达阳性,111例(69.4%)EGFR表达阳性;Syndecan-1的表达与EGFR表达显著相关(P<0.05);与K-Ras基因突变无相关性(P>0.05);Syndecan-1表达阳性患者的化疗有效率56.1%,阴性患者为40.3%(P<0.05),Syndecan-1表达阳性患者的中位无疾病进展时间为8.8个月,而阴性患者为7.2个月(P<0.05)。结论: Syndecan-1的表达对结直肠癌进展及判断预后有一定的临床价值,且与常用FOLFOX化疗方案的疗效有相关性。

关键词: 结直肠癌, Syndecan-1, 表皮生长因子受体, K-Ras, 化疗疗效

Abstract:

AIM: To investigate the relationship of Syndecan-1 and EGFR expression, K-Ras gene mutations and response to FOLFOX in advanced colorectal carcinoma.  METHODS: 160 surgical specimens of advanced colorectal carcinoma from patients consecutively treated between June 2009 and December 2014 at our hospital were collected. Immunohistochemistry method was used to screen for Syndecan-1 expression. The relationship between Syndecan-1 expression and various clinicopathological parameters, molecular markers, curative effect of FOLFOX was analyzed.RESULTS:Syndecan-1 expression was identified in the cancer cells of 41 (25.6%) colorectal cancer cases, epidermal growth factor receptor expression in 111(69.4%) colorectal cancer cases. The expression of syndecan-1 was statistically correlated with the expression of epidermal growth factor receptor (P<0.05). However, it was not significantly correlated with K-Ras mutation (P>0.05). Patients with over-expressed Syndecan-1 exhibited better efficacy on FOLFOX solution than patients presented negative Syndecan-1 expression (56.1% vs. 40.3%, P<0.05);  Patients with over-expressed Syndecan-1 also presented longer median time to progress (8.8 month vs. 7.2 month, P<0.05). CONCLUSION: The expression of Syndecan-1 is referential for evaluating the progress and the prognosis of colorectal cancer. And the expression of Syndecan-1 is statistically correlated with curative effect of FOLFOX regimens.

Key words: colorectal carcinoma, Syndecan-1, EGFR, K-RAS, curative effect of chemotherapy

中图分类号: